- Home
- WU vs TVTX Comparison
WU vs TVTX Comparison
Compare WU & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WU | TVTX |
|---|---|---|
| Founded | 1851 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2006 | 2013 |
Fundamental Metrics
Financial Performance| Metric | WU | TVTX |
|---|---|---|
| Price | $9.16 | $42.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $9.00 | ★ $35.10 |
| AVG Volume (30 Days) | ★ 6.5M | 1.4M |
| Earning Date | 04-24-2026 | 04-30-2026 |
| Dividend Yield | ★ 10.35% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $4,050,700,000.00 | N/A |
| Revenue This Year | $8.57 | $43.88 |
| Revenue Next Year | $4.71 | $33.16 |
| P/E Ratio | $5.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.85 | $13.88 |
| 52 Week High | $10.37 | $42.13 |
Technical Indicators
Market Signals| Indicator | WU | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 77.59 |
| Support Level | $9.05 | $32.62 |
| Resistance Level | $9.80 | N/A |
| Average True Range (ATR) | 0.24 | 1.98 |
| MACD | 0.05 | 0.99 |
| Stochastic Oscillator | 79.02 | 100.00 |
Price Performance
Historical ComparisonAbout WU Western Union Company (The)
Western Union provides domestic and international money transfers through its global network of over 500,000 outside agents. The company handled almost 290 million transactions in 2025 and is the largest money transfer company in the world.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.